Nanovis
Columbia City, US · 1 known investors
Nanovis develops and manufactures nanoscale surface technologies designed to improve the integration of orthopedic, spinal, and dental implants. It supplies these implant surface technologies to medical device makers and OEM partners in the medtech industry.
Founders & leadership
MH
Matthew HedrickChief Executive Officer and President
BM
Brian MoreChief Financial Officer
Board
BE
Brian EmerickChairman of Board
SG
Steve GerrishBoard Member
Investors · 1
Reported raises · per SEC filings
Form D private placements$10.9M disclosed across 6 of 7 rounds · 2014–2020
▶$5.4MraisedMar 2020 · 5 investors · BiotechnologyRule 506(b)
▶$5.4MraisedMar 2020 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- CHRISTOPHER LAMOTHEDirector
- V. EDWARD GROGGDirector
- BRIAN EMERICKExecutive Officer, Director
- MATTHEW HEDRICKExecutive Officer, Director
- BRIAN MOREExecutive Officer, Director
- Amount sold
- $5.4M
- Minimum investment
- $50K
- Sales commissions
- $220K
- Proceeds to insiders
- $237K
- Placement agents
- COMMENDA SECURITIES, LLC
- First sale
- Feb 2020
- Incorporated
- Limited Liability Company, Indiana
- Federal exemptions
- 06b, 4a5
▶$769.5KraisedSep 2017 · 5 investors · BiotechnologyRule 506(b)
▶$769.5KraisedSep 2017 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew HedrickExecutive Officer, Director
- Brian EmerickDirector, Promoter
- v Edward GroggDirector
- Brian MoreExecutive Officer, Director
- Offering amount
- $5.5M
- Amount sold
- $769.5K
- Minimum investment
- $50K
- Sales commissions
- $440K
- Proceeds to insiders
- $237K
- Placement agents
- Commenda Securities, LLC
- First sale
- Aug 2017
- Incorporated
- Limited Liability Company, Indiana
- Federal exemptions
- 06b, 4a5
▶$1.1MraisedSep 2016 · 3 investors · BiotechnologyRule 506(b)
▶$1.1MraisedSep 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew HedrickExecutive Officer, Director
- Brian EmerickDirector, Promoter
- V. Edward GroggDirector
- Brian MoreExecutive Officer, Director
- Steve GerrishDirector
- Offering amount
- $2.8M
- Amount sold
- $1.1M
- Minimum investment
- $100K
- Proceeds to insiders
- $30K
- First sale
- Sep 2016
- Incorporated
- Limited Liability Company, Indiana
- Federal exemptions
- 06b, 4a5
▶$3.8MofferedSep 2016 · BiotechnologyRule 506(b)
▶$3.8MofferedSep 2016 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steve GerrishDirector
- Brian EmerickDirector, Promoter
- Brian MoreExecutive Officer, Director
- Matthew HedrickExecutive Officer, Director
- V. Edward GroggDirector
- Offering amount
- $3.8M
- Minimum investment
- $50K
- Proceeds to insiders
- $100K
- Incorporated
- Limited Liability Company, Indiana
- Federal exemptions
- 06b, 4a5
▶$750KraisedDec 2015 · 1 investors · BiotechnologyRule 506(b)
▶$750KraisedDec 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian MoreExecutive Officer
- Steve GerrishDirector
- Matthew HedrickExecutive Officer, Promoter
- V. Edward GroggDirector
- Brian EmerickDirector, Promoter
- Offering amount
- $2.5M
- Amount sold
- $750K
- Minimum investment
- $50K
- Proceeds to insiders
- $75K
- First sale
- Nov 2015
- Incorporated
- Limited Liability Company, Indiana
- Federal exemptions
- 06b
▶$2.5MraisedJan 2015 · 1 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJan 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian EmerickDirector, Promoter
- Matthew HedrickExecutive Officer, Director, Promoter
- Brian MoreExecutive Officer, Director
- Steve GerrishDirector
- Offering amount
- $3.8M
- Amount sold
- $2.5M
- Minimum investment
- $50K
- Proceeds to insiders
- $122.5K
- First sale
- Dec 2014
- Incorporated
- Limited Liability Company, Indiana
- Federal exemptions
- 06b, 4a5
▶$372.1KraisedAug 2014 · 5 investors · BiotechnologyRule 506(b)
▶$372.1KraisedAug 2014 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian EmerickDirector, Promoter
- Matthew HedrickExecutive Officer, Director, Promoter
- Steve GerrishDirector
- Brian MoreExecutive Officer, Director
- Offering amount
- $600K
- Amount sold
- $372.1K
- Minimum investment
- $5K
- Proceeds to insiders
- $50K
- First sale
- Jul 2014
- Incorporated
- Limited Liability Company, Indiana
- Federal exemptions
- 06b, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Cqmedical13 shared keywordsCQ Medical develops patient positioning and immobilization products used in radiation therapy, including devices for brachytherapy, SBRT, SRS, and proton treatments. Its offerings serve oncology and radiotherapy clinicians treating cancer and conditions such as osteoarthritis.
Nuvasive12 shared keywordsNuVasive provides intraoperative neuromonitoring (IONM) services and implantable orthopedic and spinal devices for hospitals, surgeons, and patients, supported by board-certified neurologists and neurophysiologists. The company is transitioning its operations to Globus Medical.
Companies competing with Nanovis for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Nanovis do?
- Nanovis develops and manufactures nanoscale surface technologies designed to improve the integration of orthopedic, spinal, and dental implants. It supplies these implant surface technologies to medical device makers and OEM partners in the medtech industry.
- Who are Nanovis's investors?
- Nanovis's investors include Elevate Ventures.
- How much funding has Nanovis raised?
- Nanovis has disclosed $10.9M raised across 6 of its 7 known rounds.
- Where is Nanovis headquartered?
- Nanovis is headquartered in Columbia City, US.